GlassScriptPhysician profile
Sue A Williams
NPI 1285665190
$1,084.77
in general payments reported to CMS, 2019-2025
20 companies · $88.75 in 2025
The $88.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $142 · 2022: $36.50 · 2023: $26.15 · 2024: $244 · 2025: $88.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $199.29 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.57 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $106.24 | 2019-2022 | |
| Csl Behring | $83.34 | 2019-2024 | Kcentra |
| Pfizer INC. | $77.50 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.07 | 2019-2025 | Xifaxan |
| Abbvie INC. | $54.40 | 2024 | |
| Astellas Pharma US INC | $53.14 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $39.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.05 | 2024 | Eliquis |
| Ferring Pharmaceuticals INC. | $27.24 | 2024 | Rebyota |
| Alexion Pharmaceuticals, INC. | $26.93 | 2025 | Ultomiris |
| Insmed, INC. | $26.15 | 2023 | Arikayce |
| Aimmune Therapeutics, INC. | $25.02 | 2025 | Vowst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.18 | 2024 | |
| Vifor Pharma, INC. | $23.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.04 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.26 | 2020 | |
| Mylan Specialty L.P. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sue Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.